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ABSTRACT

PYRIDINIUM BIS-RETINOIDS A2-DOPAMINE AND A2-CADAVERINE:
IMPLICATIONS IN AGE-RELATED MACULAR DEGENERATION AND CANCER

McKenzie Ruth Pew
Department of Chemistry and Biochemistry
Master of Science

Age-related macular degeneration (AMD) is the leading cause of blindness in the
United States of America. The pyridinium bis-retinoid A2-ethanolamine (A2E) has been
implicated to play a role in AMD. We have observed novel pyridinium bis-retinoids
through melanolipofuscin and human RPE extractions that may also play a role in the
pathology of AMD. We have begun the construction of an amino-retinoid library in
order to identify these ocular compounds. The compounds from the amino-retinoid
library are also used in a targeted and triggered drug delivery system for treating cancer.
Folic acid is coupled with the amino-retinoids to specifically target cancer cells. The first
two amino-retinoids to be synthesized and characterized were A2-dopamine (A2D) and
A2-cadaverine (A2C). Both pyridinium bis-retinoids were shown to generate cytotoxic
oxidation products similar to A2E. Successful coupling of folic acid to A2C was

achieved to form the folic acid-A2-cadaverine (FA-A2C) product. Preliminary
irradiation results suggest that the FA-A2C product may be more photoreactive than
initially anticipated. This could mean less drug and light exposure required to induce
apoptosis and could eventually lead to a less invasive and toxic cancer treatment.
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CHAPTER 1. INTRODUCTION TO PYRIDINIUM BIS-RETINOIDS
1.1 Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of blindness in
the civilized world.1,2,3 The disease robs the elderly of their central vision, leaving
them unable to perform simple tasks such as cooking, driving, reading, watching
television, or recognizing faces (Figure 1). Unfortunately, despite much research, the
exact cause remains elusive partly due to its multifactorial nature involving a mesh of
metabolic, environmental, and genetic contributing factors.1,4 Consequently, there is
no cure for the disease to date.

Figure 1. Vision with Advanced AMD (left) and Normal Vision (right)
AMD can be classified into two subgroups: exudative (wet form) and atrophic
(dry form) pictured in Figure 2. Exudative AMD is typified by neovascularization,
accompanied by bleeding and fluid leakage, resulting in significant rapid vision
loss.1,2,3 Atrophic AMD is characterized by a slow deterioration of the retinal
pigment epithelium (RPE) and photoreceptor cells (Figure 3). The work related to
this part of the thesis focuses on the most common form of AMD, atrophic AMD,
which represents approximately 90% of the cases.
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Figure 2. Depiction of Dry (left) and Wet (right) Forms of AMD
Both RPE and photoreceptor cells, which are largely affected in atrophic
AMD, are postmitotic and have a symbiotic relationship. Photoreceptor outer
segments are replete with light absorbing chromophores responsible for
phototransduction. Due to constant light exposure causing oxidative stress,
photoreceptor cells are dependent on RPE cells for the phagocytosis of their discarded
outer segments.5,6 The death of one of these cells leads to the permanent loss of the
other. While not much is known about the pathogenesis of AMD and precisely what
causes the atrophy of the RPE and photoreceptor cells, it is known that at least two
processes contribute to its progression: formation of lipofuscin and drusen.1,2,4,7-10

Figure 3. Anatomy of the Eye and Retina
2

Drusen are amorphous yellow deposits that accumulate in the space between
the RPE and choroid and are considered to be the signature trait of AMD.1,3,11,12
Numerous large drusen deposits are considered to be a major risk factor in developing
advanced forms of AMD.1,11,12 Drusen is thought to negatively impact the health of
photoreceptors and RPE by physically displacing these layers, activating the immune
system, and causing inflammation.7
Another biomarker to the onset of AMD is the accumulation of fluorescent
pigments in the RPE known as lipofuscin.13,14 Lipofuscin is classified as “cellular
junk” composed of approximately 50% lipids and 44% proteins9,10,15 resulting from
incomplete digestion of cellular debris from RPE phagocytosis of photoreceptor outer
segments.16,17,18 Evidence suggests that lipofuscin deleteriously affects the RPE by
generating toxic singlet oxygen, superoxide anion, and H2O2 when irradiated with
blue light.19,20,21 The identification of the responsible chromophores could potentially
help in determining the etiology of AMD. One blue absorbing pigment has been
extensively characterized; the pyridinium bis-retinoid A2E (2-[2,6-dimethyl-8-(2,6,6trimethyl-1-cyclohexen-1-yl)-1E,3E,5E,7E-octatetraenyl]-1-(2-hydroxyethyl)-4-[4methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1E,3E,5E-hexatrienyl]-pyridinium) (1,
Figure 4).

3

N

OH

Figure 4. Structure of A2E (1)

1.2 Identification and Synthesis of A2E
Eldred and Katz22 were the first to report a series of blue absorbing
fluorophores from 250 RPE eye extracts. Eldred et al.23 used a series of silica gel
column chromatography and preparative thin layer chromatography (TLC)
purifications to successfully isolate one of the fluorophores. It was hypothesized that
this fluorophore was responsible for the fluorescence of RPE lipofuscin. An initial
structure of the fluorophore was proposed based on mass spectrometry (MS) and
basic chemical analysis of the 100 μg collection. However, structural ambiguities and
inconsistencies from the miniscule sample led Sakai et al.24 to reevaluate the
proposed structure with the aid of a synthetic standard. The synthetic fluorophore
was made from all-trans retinal (2) and ethanolamine (3) in 0.5 % yield (Figure 5).
Nuclear magnetic resonance spectroscopy (NMR) structural analysis revealed the
structure to be a pyridinium bis-retinoid, named A2E (1) for the two vitamin A
substituents and one ethanolamine moiety.
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Figure 5. Components of A2E
Since this original discovery, great improvements have been made in A2E
synthesis. Significant headway from the original 0.5% yield synthesis has enabled
further characterization and study of this molecule and its relationship to lipofuscin’s
role in AMD. Ren et al.25 were the first to report a seven step total synthesis of A2E.
However, this multi-step synthesis only provided modest yields and was not stereoselective, producing a 4:3:3:2 mixture of A2E isomers. The isomers could be almost
entirely converted to the all-trans product by heating in nitromethane.
Shortly after the report of the first total synthesis of A2E, Parish et al.26
published a biomimetic one-step preparation of A2E, combining two equivalents of
all-trans retinal with one equivalent of ethanolamine and acetic acid in ethanol. This
methodology was a marked improvement over previously reported syntheses, giving
A2E in 49% yield. The significant increase in yield was attributed to the addition of
catalytic acetic acid. This one pot process allowed for A2E preparations to be made
on a much larger scale, preparing up to 50 mg of material.
The most recent A2E synthesis to be reported was a total synthesis by Sicre et
al.27 This A2E total synthesis is an improvement over the original in that it is
stereoselective for the all-trans isomer. However, this method requires ten steps and
still only gives A2E in 14 % yield. Thus, the biomimetic approach remains the most
efficient route to synthesize substantial quantities of A2E.
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1.3 Age-Related Macular Degeneration and the Visual Cycle
A genetic predisposition to AMD has been postulated, but specific genes have
not been directly linked to the disease. However, several genes associated with
juvenile macular degeneration have been implicated to play a role in the pathology of
AMD. Some of these include the SOD2, APOE, FIBL-6, RDS, ELOVL4, and ABCA4
genes.28,29

The functions of these genes vary widely and underscore the

complexity of AMD. For instance, the RDS gene encodes a protein responsible for
maintaining the flattened shape of disks in the photoreceptor outer segments.30
Mutations in the ELOVL4 gene, predicted to play a role in the elongation of very
long-chain fatty acids in photoreceptor cells,31,32 present a phenotype that closely
resembles that seen in atrophic AMD. The phenotype includes photoreceptor
degeneration, accumulation of lipofuscin and A2E, and geographic atrophy of RPE
cells.33
The most frequently studied gene in connection with AMD is the ABCA4 or
ABCR gene. The ABCR gene is responsible for the recessive form of the childhood
macular degeneration, Stargardt’s disease,34,35 and it has been hypothesized that a
heterozygous mutation might result in a predisposition to AMD. Heterozygous
abcr+/- mice have been shown to experience delayed dark adaptation, along with
accumulation of lipofuscin and A2E.36 The ABCR gene encodes rim protein (RmP), a
photoreceptor specific ATP-binding-cassette transporter.37,38,39 During normal
phototransduction, as shown in Figure 6, a photon of light hits opsin bound 11-cis
retinal to yield free all-trans retinal (2) and opsin. All-trans retinal, in the form of Nretinylidene-phosphatidylethanolamine (NRPE, 4), is then transferred by RmP from
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the interior membrane disk to the cytoplasmic surface of the photoreceptor outer
segment where it is reduced to all-trans retinol (5) by all-trans retinol
dehydrogenase.40 The newly reduced chromophore is then transferred to the RPE
where it is subsequently esterified (6), reisomerized to the 11-cis conformation (7),
and finally oxidized back to the original 11-cis retinal (8).41 However, when ABCR
encodes a defective protein, NRPE (4) accumulates in the disk membrane where it
can combine with an additional molecule of all-trans retinal, eventually leading to
formation and buildup of A2E within the RPE cell.36,40,42

Figure 6. Enlargement of the Retina and the Visual Cycle
7

1.4 Biosynthesis of A2E
The biosynthesis of A2E has drawn a great deal of interest. Knowledge of
how this lipofuscin pigment forms, could potentially lead to targets for AMD
prevention and remedies. To this end, Mata et al.42 set out to determine the
biosynthetic precursors to A2E using abcr-/- mice as a model for AMD. The authors
claim to have identified three new compounds involved in the biosynthesis of A2E.
The first two precursors of A2E are NRPE (4), the Schiff base formed between alltrans retinal (2) and phosphatidylethanolamine (9), and A2PE-H2 (10), formed from
reaction of NRPE with all-trans retinal. Both precursors appeared to form in mice
outer segments, and were found to accumulate with age. In vitro incubation of the
purported A2PE-H2 in acidic and oxidizing conditions mimicking the RPE lysosome
environment, where lipofuscin accumulates, yielded A2PE (11) and A2E (1).42 The
biosynthesis of A2E is pictured in Scheme 1.
Lui et al.43 also identified A2E precursors NRPE (4) and A2PE (11) through
the incubation of all-trans retinal (2) in rod outer segments. The resulting precursors
were identified by high performance liquid chromatography (HPLC) analysis with
synthetic standards. NRPE and A2PE were also shown to accumulate in
photoreceptor outer segments of rat retinal tissues. The biosynthesis of these
molecules proved to be dependent on light induced release of all-trans retinal.44 The
authors also hypothesized that the hydrolysis of A2PE (11) resulted by enzymatic
processes rather than by acid hydrolysis. To prove this, A2PE (11) was incubated
with phospholipase D. HPLC analysis revealed A2E (1) formation after two hours, a

8

significantly faster rate compared to acid hydrolysis. This finding doesn’t preclude
acid hydrolysis, but lends support to the possibility of enzymatic cleavage.43,44
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1.5 Toxicity of A2E
A2E has been attributed to four different modes of RPE cell toxicity. The first
proposed mode of A2E toxicity was the disruption of cell membranes. A2E’s
ampiphilic nature enables it to insert into the lipid bilayer acting as a detergent to
disrupt cell membranes. To demonstrate A2E’s potential detergent-like nature,
Sparrow et al.45 incubated RPE cells with extracellular A2E. Two methods were used
to determine loss of membrane integrity: measuring the levels of cytoplasmic enzyme
lactate dehydrogenase (LDH) and fluorescence of a nucleic acid stain. A2E was
shown to disrupt RPE cell membranes and cause LDH leakage at concentrations of 50
and 100 μM. Nucleic acid staining revealed that exposure to 100 μM A2E for six
hours compromised 15% of nuclei. Similarly, De et al.46 used model membranes to
demonstrate that A2E caused a decrease of membrane fluidity and membrane
solubility. The amount of A2E required for the onset of membrane solubilization
depended on the membrane lipid composition. While both of these experiments did
demonstrate A2E’s potential toxicity as a detergent, the levels of the pyridinium bisretinoid required for the effect were well above those found in human RPE cells.
However, work by Schutt et al.47,48 showed that A2E disrupted organelle membranes
at low physiologically relevant concentrations. Mitochondria, lysosome and
microsome leakage was observed at 1, 2, and 5 μM of A2E, compared to more than
100 μM required for cellular membranes.
A2E and lipofuscin have both been shown to localize in the lysosomes of RPE
cells.45,49 Accordingly, lysosomes would be a logical target for A2E toxicity and
Finnemann et al.49 explored this relationship. RPE cells incubated with 100 μM A2E
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showed slower outer segment degradation compared to control RPE cells. The
authors found that while A2E loaded lysosomes did not inhibit protein degradation, it
did impair outer segment lipid degradation, specifically phosphatidylcholine. It was
hypothesized that the lack of lipid degradation was a result of A2E’s selective
inhibition of lipid hydrolases or blocking of lipid trafficking into subcompartments.
The end result would be a build up of undigested lipids in RPE cells over time.
Bergman et al.50 used isolated intact A2E fed lysosomes to demonstrate ATPase
activity, a measurement of lysosomal proton pump activity, was reduced by 50 % at 1
μM A2E and 90 % at 2 μM A2E concentrations. The proton pump was also shown to
be affected by A2E through the increase of lysosomal pH. It was concluded that A2E
directly interacts with the proton pump and inhibits its activity, eventually resulting in
decreased photoreceptor outer segment phagocytosis and degradation.
A third reported A2E toxicity mechanism is disruption of mitochondrial
function. It was thought that because mitochondria establish a negative charge inside
their inner membrane that it would drive lipophilic cations, like A2E, into the
organelle. Suter et al.51 incubated cerebellar granule cells, known for their high
mitochondria content, with 5-20 μM A2E. Apoptosis, along with release of the
proapoptotic proteins cytochrome c and apoptosis inducing factor (AIF), was
observed in cells with concentrations >10 μM of A2E. Isolated mitochondria from
the cells showed decreased oxygen consumption. Specifically, A2E was found to
bind tightly, but non-covalently, to cytochrome c oxidase. Exposure to light
increased A2E’s inhibition of the enzyme and permanently altered its function.
Ultimately, A2E’s binding with cytochrome c oxidase prevented the binding with
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cytochrome c, interrupting the electron flow, increasing oxidative stress, and resulting
in apoptosis.52 While it was demonstrated that A2E did inhibit mitochondria function
at low biologically relevant concentrations, it has also been shown that A2E does not
accumulate in RPE mitochondria.45
The majority of A2E research has centered on its potential phototoxicity. If
A2E is the major blue absorbing fluorophore in lipofuscin, then it should also be
responsible for the induced phototoxicity. Because of this hypothesis, Sparrow et
al.53 tested the blue light phototoxicity of A2E on human adult RPE cells free of
endogenous A2E. Cell cultures were incubated with 10, 50, and 100 μM A2E,
resulting in intracellular accumulation at levels measured from healthy human donor
eyes, and then irradiated with blue light. After irradiation, RPE cell viability was
assayed and showed that 100 μM A2E killed 75% of the cell culture, while 10 μM
A2E did not have a measurable impact. Cell apoptosis was demonstrated to be a
function of both A2E concentration and light exposure.
The executioners responsible for A2E apoptosis were additionally
investigated. Cells incubated with A2E showed caspase-3 activity five hours after
irradiation. Furthermore, addition of the caspase-3 inhibitor, Z-DEVD-fmk,
decreased A2E photoinduced apoptosis by 55%. To determine if Bcl-2, an
antiapototic protein, expression could also attenuate cell death, RPE cells were
transfected with a plasmid containing cDNA for human Bcl-2. The transfected cells
showed a 50% reduction in apoptotic nuclei, suggesting that A2E photoinduced
apoptosis is executed by a caspase cascade which is regulated by Bcl-2.54
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DNA is known to be damaged by reactive oxygen species, and therefore
considered a potential target of A2E phototoxicity. Once again, Sparrow et al.55
incubated human RPE cells with 20 μM A2E and exposed the incubated cells to blue
light. Comet assays showed over 95% of the cells suffered DNA damage and the
number of strand breaks was proportionate to the duration of light exposure.
Addition of sodium azide, a singlet oxygen quencher, to A2E containing cells reduced
the number of DNA strand breaks, which indicates that singlet oxygen plays a role in
A2E blue light toxicity. Additional evidence for the role of singlet oxygen was
provided by DNA repair enzymes that showed cells suffered from oxidized purine
and pyrimidine bases. Avidin and monoclonal antibodies specifically identified
formation of the common oxidative DNA lesion 8-oxo-deoxyguanosine (13, Figure
7). Finally, it was also observed that the ability of RPE cells to repair damaged DNA
declined with increasing severity of injury. Not only does this evidence suggest A2E
is capable of causing photoinduced DNA damage, and eventually apoptosis, but it
also indicates damage is mediated through singlet oxygen.
O
O O
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H
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Figure 7. 8-Oxo-deoxyguanosine (13)
To further elucidate A2E’s mechanism in blue light photoinduced toxicity,
Ben-Shabat et al.56 directly irradiated the pyridinium bis-retinoid with blue light. MS
analysis of the sample after ten minutes of blue light exposure revealed a series of m/z
+16 oxidative product peaks corresponding to the addition of oxygen atoms to the
13

carbon-carbon double bonds of A2E. Up to nine oxidation products were observed
by MS, meaning that potentially nine oxygen atoms were added to one molecule of
A2E. Upon NMR studies of a synthetic A2E oxidation product generated by reaction
with meta-chloroperoxybenzoic acid (MCPBA), the authors assigned the structure to
be a bis-oxirane (14).
It was hypothesized that singlet oxygen might be responsible for the formation
of these polyoxidation products. To test this theory, A2E was irradiated in the
presence of singlet oxygen enhancer D2O. HPLC analysis demonstrated the
disappearance of A2E to be 3 fold greater in D2O compared to H2O. It was
concluded that the excited states of A2E were quenched by triplet oxygen producing
singlet oxygen, which in turn was efficiently quenched by A2E to form the observed
polyoxidated products. The highest molecular ion product purportedly corresponded
to the formation of a nonaoxirane (15).
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OH
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Bis-oxirane (14), m/ z 624
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OH

Nonaoxirane (15), m/ z 736

Figure 8. A2E Photooxidation Products
The A2E epoxide investigation was extended to generation of photooxidation
products in human RPE cells. RPE cells were incubated with A2E, followed by
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exposure to blue light. The irradiated culture was then extracted and subjected to MS
analysis. As previously seen with irradiated A2E solutions, the RPE cellular extracts
also contained a series of polyoxidative products. The involvement of singlet oxygen
in the formation of these photooxidation products was further implicated when A2E
containing cells in deoxygenated media were exposed to blue light. RPE cell death
was decreased by 98%. Cell death could also be attenuated by incubating A2E
containing cell cultures with singlet oxygen quenchers such as sodium azide and
histidine. A 43% decrease in cell death was observed with 1 mM of sodium azide,
while a 23% reduction in nonviable cells resulted from 10 mM of histidine
incubation. Addition of D2O to cell cultures exhibited the opposite effect and an
increase of 66% in nonviable cells was observed.57 Photooxidation of A2E was also
shown to take place in vivo. Albino abcr -/- mice lacking melanin, the pigment
responsible for absorbing extrapupillary and scattered light, were exposed to cyclic
light. The mice eyecups were subsequently isolated and the resulting organic
material extracted. While both albino and pigmented mice had a similar amount of
A2E, albino mice presented a 1.5 fold higher level of oxidized A2E. The greater
amount of oxidized A2E present in albino mice suggests that the biosynthesis of A2E
and its conversion to polyoxidated products is dependent on increasing amounts of
light.58
DNA was once again revisited as a potential target of A2E photochemistry,
but with A2E epoxides directly reacting with DNA. To test this interaction, A2E
epoxides were generated through irradiation and then incubated with human RPE
cells. The comet assay was used to test for epoxide reactions with DNA. Only cells
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incubated with the oxidized A2E showed a significant amount of DNA strand breaks
compared to control cells containing unoxidized A2E. DNA cleavage was also
observed in cells that were incubated with synthetic bis-oxo-A2E made from reaction
with MCPBA. The use of monoclonal antibodies revealed that cells incubated with
oxidized A2E tested positive for the common oxidative DNA lesion 8-oxodeoxyguanosine (13). Furthermore, the antioxidants vitamins E and C were proven to
suppress the formation of A2E oxidation products and blue light induced DNA strand
breaks in RPE cells. This evidence, combined with the knowledge that DNA repair
mechanisms and antioxidants decrease with age, implies that DNA and other cellular
macromolecules may be targets for A2E-epoxide elicited cell death.59
Recently the validity of the formation of a nonaoxirane (15) was brought into
question due to its instability and the structure of the A2E oxidation product was
reevaluated.60 Jang et al.61 reacted A2E with MCPBA to generate the partially
oxidized A2E. Heteronuclear single quantum correlation (HSQC) NMR clarified the
structure to be a 5,8,5′,8′-bis-furan-A2E (16, Figure 9) instead of the previously
suggested 7,8-epoxide. Reaction with the singlet oxygen generator 1,4dimethylnaphthalene yielded a product corresponding to the addition of four oxygens,
but with an ultraviolet-visible (UV-Vis) absorption spectrum showing addition
occurring at only one double bond on both long and short arms of A2E. Subsequent
proton and HSQC-NMR analysis revealed the structure to be 5,8,5′,8′-bis-peroxyA2E (17).
In order to better characterize the A2E oxidation products previously seen in
cellular environments, human RPE cells were once again incubated with A2E and
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irradiated with blue light. Liquid chromatography-mass spectrometry (LC-MS)
analysis of chloroform extracts showed two product peaks of m/z 608 and 624 with
similar UV-Vis spectra having hypsochromic shifts occurring only on the shorter arm
of A2E. On the basis of the new structural assessments of oxo-A2E products, these
cellular oxidation products were assigned to be the mono-furanoid and monoperoxide, respectively. The mono-furan-A2E (18) and mono-peroxy-A2E (19) were
also shown to occur in vivo as they were found in both human donor RPE and
abca4/abcr -/- mice posterior eye extracts. According to the new structural
assignments it appears that upon oxidation, A2E initially forms an epoxide at the
electron rich 5,6 double bond, and then depending on the environment, such as the
acidic environment of lysosomes or MCPBA, likely rearranges to the more stable 5,8furanoid product in the RPE. Instead of epoxidation occurring at every double bond
of A2E, as presumed with the nonaoxirane (15), a more likely explanation is that the
higher molecular weight oxidation products result from a [4+2] cycloaddition with
singlet oxygen. The newly observed A2E-endoperoxides are relatively unstable and
are anticipated to promote reactivity within the cell, causing significant RPE death.61
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Figure 9. Revised A2E Oxidation Products

1.6 Photophysical and Photochemical Properties of A2E
In order to better understand the relationship between A2E and lipofuscin
phototoxicity in AMD, the photophysical and photochemical properties of A2E have
been extensively studied. The primary photophysical properties of A2E were first
studied by Lamb et al.62 wherein they calculated the emission quantum yield in
ethanol to be 0.01. From this it was concluded that A2E’s main relaxation process
was through a nonradiative mechanism. Comparison of A2E photoacoustic signals to
a standard solution indicated that the absorbed energy is almost quantitatively
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converted into heat. Contrary to the nonexponential decay observed for lipofuscin,
the emission decay for A2E was found to be exponential with a 12 picosecond (ps)
time constant, leaving little time for energy transfer to singlet oxygen. The authors
also calculated the quantum yield for generation of molecular singlet oxygen from
emission intensities to be 0.02 and concluded that A2E is not an efficient generator of
singlet oxygen or the major phototoxin of lipofuscin.
The generation of singlet oxygen was directly measured by Kanofsky et al.63
using steady state irradiation and cholesterol as a singlet oxygen trap. Singlet oxygen
phosphorescence detection for A2E showed the quantum yield to be 0.013.
Cholesterol hydroperoxide (ChOOH) measurements showed A2E singlet oxygen
generation to be small compared to a known singlet oxygen generator standard. A2E
singlet oxygen generation was also compared to its retinal precursor. Solutions of
A2E and all-trans retinal dissolved in liposomes both demonstrated photoproduction
of ChOOH from cholesterol. However, all-trans retinal consumed oxygen at 20.6
times the rate of A2E. An interesting observation gleaned from this experiment is
that while photoexcited all-trans retinal generated only singlet oxygen, A2E produced
both singlet oxygen and free radicals, although inefficiently. From the comparison of
the photoreactivity of all-trans retinal and A2E, Pawlek et al.64 concluded that the
generation of singlet oxygen and free radicals by A2E is insufficient to account for
the photoreactivity of lipofuscin. Moreover, they claimed that A2E is an efficient
protective agent against all-trans retinal phototoxicity.
To further study the potential phototoxicity of A2E, Pawlek et al.65 monitored
the photoconsumption of oxygen by lipofuscin, lipofuscin extracts, and A2E.
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Lipofuscin granules, liposomes containing lipofuscin extract, and the chloroform
insoluble lipofuscin material all showed similar photoinduced oxygen uptake. Thus,
the lipofuscin granule photoactive materials were also present in lipofuscin extracts.
A2E’s oxygen consumption was measured and found to follow the absorbance
spectra. However, it did not resemble the action spectra for lipofuscin. The authors
proposed that A2E is not a significant contributor to lipofuscin’s photoinduced uptake
of oxygen. Additionally, the photoreactivity of A2E was directly compared to that of
lipofuscin by irradiating liposome dissolved samples with blue light. Extracts were
measured to consume a significant amount of oxygen, while the oxygen consumption
of A2E was undetectable. At most, A2E could only account for 25% of the oxygen
consumption of the lipofuscin extract. The above results postulate that there must be
other more prevalent and toxic blue absorbing chromophores responsible for the
generation of reactive oxygen species in lipofuscin.

1.7 Detection of New Lipofuscin Fluorophores and Amino-Retinoid Library
While the photophysical and photochemical properties of A2E argue that it
does not play a role in the pathology of AMD, the evidence from multiple cellular
assays demonstrating A2E’s photoinduced apoptosis cannot simply be
ignored.53,54,55,59 The photophysical findings do not preclude the role of A2E in the
etiology of AMD. However, the comparison of the photoreactivity of A2E and
lipofuscin does illustrate the need for further identification and study of all of
lipofuscin’s components. To this end, one of the goals of our research is to identify
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the remaining blue absorbing chromophores of lipofuscin, specifically new
pyridinium bis-retinoids.
Originally, Eldred22,23 isolated the first fluorophore from pooled lipofuscin
extractions. Similarly, we have found new unidentified lipofuscin components
through organic extractions and HPLC purification. Extractions were also performed
on human donor RPE for comparison. Initial structural investigations of the new
fluorophores were conducted using a combination of MS and HPLC analysis. Just as
the final structural elucidation of A2E required the use of a synthetic standard,24 an
amino-retinoid library was constructed in our laboratories using biogenic amines
commonly found in the eye for the final characterization of the extracted aminoretinoids.

1.8 Targeted and Triggered Drug Delivery System
The formation of an amino-retinoid library serves a dual purpose in our
research. In addition to identifying fluorophores implicated in the pathology of
AMD, the standards are also used to create compounds for the development of a
targeted and triggered cancer treatment. Current cancer chemotherapies are invasive
and mostly indiscriminant and thus highly toxic to both healthy and cancerous cells.
Recent evidence suggests that folic acid may offer a way to specifically target cancer
cells, leaving normal cells reasonably unharmed. The folate receptor has been shown
to have increased expression in certain malignant tissues, up to two orders of
magnitude greater than found in normal tissue.66 Folate receptor α has a higher
expression in ovarian,67 brain,68 kidney,66 cervical,69,70 breast,71 and pancreatic72
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cancers. Another isoform, folate receptor β, is mostly associated with leukemia,
specifically chronic myelogenous leukemia73 and acute myelogenous leukemia.74
Both folate receptor isoforms are known to bind and uptake folic acid with high
affinity at low physiological concentrations.75 This, combined with the evidence that
most normal tissues virtually lack the folate receptor, along with folic acid’s ease of
modification, ready availability, low cost, and stability during storage, make the
folate receptor an attractive target.76 An additional mechanism of protection for
healthy cells expressing the folate receptor is provided by the cell’s polarization
wherein the folate receptor is attached to the apical surface of epithelial cells, out of
direct contact with circulating folic acid labeled toxins.77 However, cancer cells
typically lose their polarization, making the folate receptor accessible to folates in
circulation.77,78 Several drugs have shown increased success through the targeting of
the folate receptor,79-84 and it is this way that we plan to target our treatment.
Pyridinium bis-retinoids from our synthetic library will be tethered to folic acid by
standard coupling procedures, shown in Scheme 2, to selectively kill malignant
tissues.
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Scheme 2. Targeting Pyridinium Bis-Retinoids with Folic Acid
The trigger for our system is light. Our targeted and triggered drug delivery
system is based on principles of photodynamic therapy. Photodynamic therapy
involves the administration of a photosensitizer which, through various mechanisms,
localizes into the tumor tissue.85,86 In our targeted and triggered drug delivery system
the photosensitizer is selectively taken up by folate receptor positive malignant cells.
The photosensitizer is then activated by light which transforms the drug into an
excited state. From this point the drug can interact with surrounding cellular
components transferring a hydrogen atom or electron to form radicals, which can then
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react with oxygen to produce oxygenated products. Alternatively, the excited drug
can transfer its energy to oxygen, generating cellular damaging singlet oxygen.87
A2E has been repeatedly shown to induce apoptosis when irradiated with blue
light,53,54,55,59 and other pyridinium bis-retinoids have been shown in our laboratories
to behave in a similar manner. The mechanism implicated in the photoinduced death
involves cellular reaction with A2E polyoxidation products generated through the self
quenching of singlet oxygen.55,56,59 Figure 10 shows a schematic of our proposed
targeted and triggered drug delivery system. The normal cell has a low expression of
the folate receptor (green) and thus minimal uptake of the folate labeled pyridinium
bis-retinoid (yellow and orange). However, the cancer cell shows significant folate
receptor expression and uptakes the drug preferentially. Upon exposure to blue light
the cancer cell undergoes apoptosis, while the healthy cell is left unharmed.

Figure 10. Depiction of Targeted and Triggered Drug Delivery System
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Our proposed targeted and triggered drug delivery system offers three
advantages over traditional cancer therapies. First, folic acid will be used to
specifically target cancer cells. Targeting with folic acid may also decrease the
amount of drug needed to induce apoptosis. Unlike other drug delivery systems
which are trafficked directly to the lysosome for destruction, thus requiring higher
concentrations to elicit fatality, folic acid labeled drugs are recognized by the cell and
consequently retained in the cytoplasm where they are most effective.88 A second
advantage is that folic acid is minimally toxic and A2E, in the unoxidized form, is
well tolerated at relatively high concentrations (up to 100 μM)53 compared to typical
cancer treatments. Finally, cytotoxicity can be triggered by irradiation only to the
affected area, thus minimizing toxicity to surrounding healthy tissue. Based on these
three properties, our targeted and triggered drug delivery system could potentially
offer a less invasive and toxic alternative to the current slash and burn cancer
treatments available.
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CHAPTER 2. INDENTIFICATION OF NEW FLUOROPHORES
In an effort to better define lipofuscin’s role in the pathology of AMD and to
reconcile the differences in the photoreactivity of lipofuscin and A2E, a central goal
of our research is to identify the remaining blue-absorbing lipofuscin chromophores.
Similar to the original experiments by Eldred and Katz1 used to isolate A2E, we also
performed extractions on lipofuscin, melanolipofuscin, and human donor RPE
samples. The extraction protocol is based on the method reported by Parish et al.2

2.1 Extraction of Human Lipofuscin, Melanolipofuscin, and RPE
Samples of lipofuscin and melanolipofuscin, melanin pigment fused with
lipofuscin granules,3,4,5 were prepared and donated by Dr. Craig Thulin and
researchers. The prepared eye samples were first homogenized and then extracted.
The chloroform (CHCl3) soluble material was collected and analyzed by reversedphase HPLC. The resulting HPLC chromatogram from the melanolipofuscin sample
is shown in Figure 1a. A2E, highlighted in red, was identified in the
melanolipofuscin extract by its standard retention time and characteristic camel back
shaped UV-Vis spectrum. We also observed two other unknown prominent peaks
(blue) that were not all-trans retinol, retinal, or A2E oxidation products based on
comparison to known spectral data. The two peaks presented UV-Vis spectra similar
to A2E, but it was determined that they were not isomers due to their large relative
peak areas. Iso-A2E, the most abundant isomer, is known to exist in a 1:4 ratio with
A2E2 and other isomers are substantially less prevalent.6 It was hypothesized that
these two peaks belonged to new pyridinium bis-retinoid compounds. To test this
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hypothesis, a co-injection of the melanolipofuscin extract and synthetic standard A2E
was performed to corroborate that the two putative pyridinium bis-retinoid peaks did
not belong to A2E or its isomers. The resulting co-injection HPLC chromatogram
shown in Figure 1b confirms our hypothesis that the unidentified blue-absorbing
chromophores are not A2E or any of its isomers. This was concluded from the
increase in A2E (red) peak area ratio relative to the putative novel pyridinium bisretinoids (blue) resulting from the co-injected standard.

Figure 11. (a) Chromatogram of Melanolipofuscin Extract: A2E (red), New
Chromophores (blue); (b) Co-injection with A2E Standard
In addition to observing new pyridinium bis-retinoid compounds in lipofuscin,
we have also detected a new pyridinium bis-retinoid in human donor RPE eye
extracts, indicating that the melanolipofuscin fluorophores were not merely an
artifact. Figure 2 shows the HPLC chromatogram from one of the RPE eye extracts.
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Once again A2E is highlighted in red and the putative pyridinium bis-retinoid in blue.
Figure 2b shows the unidentified pyridinium bis-retinoid’s UV-Vis spectrum which
has the classic camel back shape similar to A2E.

Figure 12. (a) Chromatogram of RPE Extract: A2E (red), New Chromophore
(blue); (b) UV-Vis of New Chromophore
While the identity of these putative pyridinium bis-retinoids are at present
unknown, a common trend can be seen in both the melanolipofuscin and RPE
extracts. In each of the HPLC chromatograms the unidentified fluorophores have a
shorter retention time than A2E, meaning they are more polar. This information has
provided a direction for us in which to start looking. To this end, we began building a
pyridinium bis-retinoid library combining polar biogenic amines commonly found in
the eye with all-trans retinal in an attempt to identify these compounds. Figure 3
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shows prospective biogenic amines that are presumably more polar than ethanolamine
and that are being used in our library.
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Figure 13. Biogenic Amines to be Used in Pyridinium Bis-Retinoid Library
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CHAPTER 3. STUDIES OF PYRIDINIUM BIS-RETINOID A2-DOPAMINE
Upon the discovery of potential new pyridinium bis-retinoids in human
melanolipofuscin and RPE extractions, our focus turned to identifying these
biological compounds by constructing a library of pyridinium bis-retinoids. In
beginning to build our library, one of the new amines of choice was dopamine (21,
Figure 1). Dopamine was selected as a starting point for two reasons. First, the
resulting amino retinoid would presumably be more polar than A2E on reversedphase HPLC, thus correlating to the new amino retinoid compounds observed.
Second, dopamine has the ability to generate free radicals.1,2,3 The ability of
dopamine to generate reactive oxygen species, known as dopamine toxicity, was an
attractive property for our targeted and triggered cancer drug delivery system.
Theoretically, more free radicals generated would result in more cytotoxic oxidation
products and hopefully increased cell fatality.
OH
OH
H 2N

Figure 14. Dopamine (21)

3.1 Synthesis of A2-Dopamine
The proposed route for constructing the amino retinoid library was to use a
biomimetic method reacting all-trans retinal with the desired amine. A biomimetic
route was chosen over total synthesis for three fundamental reasons. First, current
multi-step A2E total syntheses report low overall yields (around 14 %),4 while the
biomimetic method gives A2E in one-step in 49% yield.5 The second reason is that a
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biomimetic approach is a simple one step and one pot reaction, compared to a ten step
total synthesis.1 Finally, the amines are generally economical and readily available.
All-trans retinal (2) can be easily synthesized from inexpensive vitamin A propionate
(22) or purchased directly, making the overall synthesis even easier.
The first step in constructing our amino retinoid library was to synthesize the
starting material all-trans retinal (2) from vitamin A propionate (Scheme 1). Vitamin
A propionate (22) was hydrolyzed to retinol (5) with potassium carbonate (K2CO3) in
a 10:1 methanol (MeOH), tetrahydrofuran (THF) solution.6 The resulting retinol (5),
typically isolated in 80 % yield, was then oxidized by manganese dioxide (MnO2) to
give all-trans retinal in 85 % yield (2).7
O
O
Vitamin A Propionate (22)

OH
all-trans Retinol (5)

K2CO3
MeOH, THF

MnO2
CH2CL2

OH
all-trans Retinol (5)

O
all-trans Retinal (2)

Scheme 3. Synthesis of all-trans Retinal (2)
With the starting material in hand, we had two biomimetic options for
synthesizing the dopamine retinoid compound. Pezzela et al.8 had previously
reported a synthesis for the dopamine mono-retinoid (A1D) using a 0.1 M phosphate
buffer at pH 7.4 with 1-2% w/w sodium dodecylsulfate (SDS) to mimic the eye’s
biological environment. The second option for synthesizing the dopamine retinoid
compound was to use the standard conditions for synthesizing A2E reported by Parish
et al.5 This method combined all-trans retinal and the desired amine in ethanol and
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acetic acid. Because Pezzela8 only reported formation of the mono-retinoid it was
presumed that both methods would yield only A1D and not the pyridinium bisretinoid. Theoretically, both the tetrahydroisoquinoline retinoid, A1D, and
pyridinium bis-retinoid, A2-dopamine (A2D), have a chance of forming. Once
dopamine (1) has attacked the aldehyde (2) to form the Schiff base intermediate 23,
there are two diverging pathways that can follow (Scheme 2). The Schiff base
intermediate 23 can either undergo a [1, 5] H-shift, as in the case of A2E, giving the
secondary amine 24. The secondary amine 24 can subsequently react with another
molecule of all-trans retinal to give the pyridinium bis-retinoid A2D (25).
Alternatively, intermediate 23 can follow another pathway involving a PictetSpengler reaction where the electron donating hydroxy groups of dopamine facilitate
the attack of the Schiff base adduct to give tetrahydroisoquinoline products 26 and 27,
collectively referred to as A1D.
Three reactions were initially used in the synthesis of the dopamine retinoid
compound to discover conditions which optimized yield and purity. Two of the three
reactions were carried out under the Parish5 method which combined dopamine (HCl)
and all-trans retinal in ethanol. An equivalent of acetic acid (AcOH) was added to
only one of the two reaction flasks to see if it improved yields. The third reaction
combined dopamine (HCl) and all-trans retinal in 0.1 M phosphate buffer (pH 7.4)
with 1.5% w/w SDS. All reactions were stirred at room temperature, in the dark to
minimize any decomposition or photoisomerization of materials.
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Scheme 4. Two Pathways in the Reaction of all-trans Retinal and Dopamine
Surprisingly, the two biomimetic methods gave drastically different outcomes.
According to the fast atom bombardment-mass spectrometry (FAB-MS) results, the
two reactions using the standard A2E protocol (Method I, Figure 2) gave only the
anticipated A1D (420 m/z, 26 and 27) products. The reaction containing acetic acid
returned more product. However, the physiological conditions reported by Pezzella8
(Method II, Figure 2) gave the previously unreported pyridinium bis-retinoid, A2D
(684 m/z, 25), as the major amino retinoid product.
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Figure 15. A2D Synthesis FAB-MS Results (a) Method I with Acetic Acid, (b) Method I without Acetic Acid, (c) Method II
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Limited attempts were made to alter the outcomes of the two methods by varying
amounts of all-trans retinal. One equivalent of all-trans retinal was used to select for the
tetrahydroisoquinoline retinoid products, while two equivalents were used to encourage
the formation of the pyridinium bis-retinoid. Regardless of the conditions used, the
outcomes were the same. Method I still gave the mono-retinoid with two equivalents of
retinal, and Method II yielded the pyridinium bis-retinoid with only one equivalent.
The surprising discovery of A2D proved advantageous since one of the purposes
of constructing our library is to identify the pyridinium bis-retinoid compounds seen in
the human eye extractions. To this end, A2D was synthesized according to Pezzella’s8
conditions, extracted from the aqueous buffer, purified by column chromatography, and
repurified by chromatotron. A2D was isolated in 20 % yield and the identity was
confirmed by UV-Vis, high resolution electrospray ionization mass spectrometry (HRESI-MS), and 1H/13C NMR. Proton and carbon NMRs revealed the dodecyl sulfate anion
to be the counterion to A2D. Figure 3 shows a comparison of the A2D UV-Vis spectrum
(a) and its near identical resemblance to the camel backed shape spectrum of A2E (b).
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Figure 16. Comparison of UV-Vis Spectra (a) A2D, (b) A2E standard.
In summary, we were able to biomimetically synthesize, isolate, and characterize
the pyridinium bis-retinoid A2D. The dopamine bis-retinoid was isolated in 20 % yield.
While this is lower than the 50 % yield reported for biomimetically synthesized A2E, it is
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still more economical than the ten step and 14 % overall yield total synthesis alternative.
In addition, we demonstrated that the two different biomimetic approaches gave two
different amino retinoid products. In fact, the conditions used by Pezzella8 actually
yielded A2D (25) as the main amino retinoid product, contrary to that reported. It is
unclear as to why the two biomimetic methods gave different results since both used
protic solvents (Method I: ethanol; Method II: water) to run the reaction. The outcome in
Method II was presumably a consequence of either the buffer or SDS that favored the
formation of the pyridinium bis-retinoid. With the finding that the biologically relevant
conditions reported by Pezzella actually yield the pyridinium bis-retinoid over the
tetrahydroisoquinolines, one might hypothesize that the bis-retinoid would form
preferentially to the mono-retinoid in the lipid rich aqueous environment of the eye.

3.2 A2D Photochemical Experiments
With A2-Dopamine in hand the next step in our project was to test the pyridinium
bis-retinoid for potential photooxidation capabilities. If A2D demonstrated photoinduced
oxygen uptake similar to A2E not only could it potentially play a role in the pathology of
AMD, but it could also make an effective phototoxin for our targeted and triggered drug
delivery system. Because dopamine is known to generate reactive oxygen species it was
hoped that A2D would be oxidized more efficiently than A2E. To test this hypothesis
A2D was dissolved in a 10% dimethylsulfoxide (DMSO) solution in water. The sample
was irradiated in a two sided polystyrene visible cuvette using a dichroic blue filter.
Aliquots of the irradiated A2D were taken every hour for five hours and submitted for
electrospray ionization-mass spectrometry (ESI-MS) analysis.
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Figure 17. A2D Irradiation ESI-MS Results for Hours 0, 1, 3 and 5
The ESI-MS irradiation results for hours one, three, and five are shown in Figure
4. Beginning with time = 0, the pure sample solution shows one single clean product
peak at m/z 684 belonging to the pyridinium bis-retinoid A2D. After one hour of blue
light exposure one can observe the appearance of four oxidation products in increments
of m/z 16 starting from the M+ peak. The first peak (700), exactly m/z 16 greater than
A2D, corresponds to the addition of one oxygen atom. The second (716), third (732),
and fourth (748) peaks are associated with the addition of two, three, and four oxygen
atoms to the pyridinium bis-retinoid arms. Further blue light exposure results in a
decrease of the original oxidation products (m/z 700 and 716), and simultaneously yields
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additional product peaks at m/z 764, after three hours, and 780 after five hours of
irradiation. These results correspond to the formation of polyoxidative species with at
least six oxygen atoms added onto the A2D retinoid arms.
While A2D does appear to yield polyoxidative species similar to A2E when
irradiated with blue light, its oxidation mechanism differs in several aspects. For
instance, A2D’s most abundant oxidation product is m/z 700, corresponding to the
addition of one oxygen atom. Typically, A2E forms the bis-oxo preferentially to the
mono-oxo A2E. Also, when A2E is irradiated with blue light it is almost completely
consumed. However, from mass spectrometry data it appears that the majority of A2D
oxidation takes place within the first hour of light exposure. From this point it appears
that only the mono and bis-oxo A2D, not the starting material, are further oxidized to
form the polyoxidative A2D species. This is concluded from the decrease in m/z 700 and
716 peak ratios compared to the virtually unchanging A2D peak (684). This result can be
explained by the fact that conjugation in the A2D oxidation products has been broken,
and therefore they are more likely to react with singlet oxygen over the original A2D.
Finally, A2E has been shown to generate nine photooxidation products by mass
spectrometry, compared to A2D’s six. It was initially hypothesized that upon irradiation
with blue light, epoxidation would occur at all nine double bonds on the bis-retinoid arms
of A2E, forming a nonaoxirane.9 However, the feasibility of the formation of a
nonaoxirane was questioned due to the instability of a molecule containing nine epoxides.
More recently it was suggested that epoxidation begins at the 5,6 double bond of amino
bis-retinoids, and in some cases rearranges to form a 5,8-furanoid product.10,11 In
addition to this, it was found that the more highly oxygenated bis-retinoid products are
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likely polyperoxide species resulting from a [4+2] cycloaddition between singlet oxygen
and two double bonds, instead of epoxidation occurring at every double bond.11 Based
on this information, we conclude that the observed oxo-A2D products are also a
consequence of epoxidation and [4+2] cycloadditions with singlet oxygen. Figure 5
shows a selection of potential A2D oxidation products such as the epoxide (28), bis-furan
(29), peroxyexpoxide (30), and the bis-peroxy-A2D (31). Clearly it would be impossible
to determine by NMR the exact structure of these A2D photooxidation products due to
the small quantities, instability, and multiple isomers of the species formed. The
structure of the oxo-A2D products are speculative based on the current findings, which
are still heavily debated in the literature.
Unfortunately, it appears that A2D does not oxidize as efficiently as A2E.
However, it has been demonstrated that some A2D photooxidation does take place in
vitro, and therefore is likely to occur in vivo and could potentially play a role in the
observed phototoxicity of lipofuscin. Additionally, while A2D may not be as
photoreactive as A2E, its oxidation properties make it useful in our targeted and triggered
drug delivery system.
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3.3 Coupling of Folic Acid to A2D
In addition to identifying new amino bis-retinoids in human eyes, our project
included using the library of synthesized amino retinoid compounds as potential anticancer therapies. Once A2D had been isolated and its potential photooxidation
demonstrated, the next step was to tether A2D to folic acid (20) yielding folic acid-A2dopamine (FA-A2D). The coupling of A2D to folic acid would allow us to specifically
target cancer cells, while leaving healthy normal cells untouched. Our plan to
accomplish this task, shown in Scheme 3, was to activate the α and γ carboxylic acid
groups of folic acid with dicyclohexylcarbodiimide (DCC), using 4dimethylaminopyridine (DMAP) as the catalyst. It was anticipated that the reaction
would potentially give at least four FA-A2D products (32, 33, 34, 35) resulting from
dopamine’s two different hydroxyl groups potentially attacking either the α or γ
carboxylic acid of folic acid. Initial attempts to selectively protect one of the carboxylic
acids were not made because the starting materials were costly. The purpose of this
reaction was to see if it was possible to directly link folic acid to a pyridinium bisretinoid, as the coupling of folic acid to this type of compound had never been reported in
the literature.
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The FA-A2D reaction was carried out in dark and dry conditions under N2 by first
activating folic acid (20) with DCC, followed by addition of the catalyst, DMAP, and the
pyridinium bis-retinoid, A2D (25). Large excesses of folic acid, DCC, and DMAP were
used in this first attempt to ensure the reaction would go to completion. The reaction’s
progress was tracked for 24 hours by HPLC starting at 5 minutes. From the HPLC
results in Figure 6 (1), it seems that there is a series of initial complexes forming between
folic acid and A2D after only 5 minutes of reaction time. This is evidenced by the
formation of several new peaks (A, C, and D) with corresponding UV spectra that appear
to be a combination of folic acid (λmax=283 nm) and A2D (λmax= 339.8, 441.6 nm,
DMSO). Peak B corresponds to the starting material A2D.
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Figure 19. HPLC Chromatogram and Corresponding UV-Vis Spectra from FAA2D Reaction (1) time=5 minutes, (2) time= 24 hours
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Figure 7 illustrates the UV-Vis spectra of starting materials, folic acid (red) and
A2D (green), and the initially proposed folic acid-A2D complex (purple). Although the
purple spectrum looks like it may be the FA-A2D complex, because of the nice overlay
with the starting materials, we were skeptical because ester bond formation is typically
not immediate. This skepticism was supported by HPLC results after 24 hours of
reaction time (2) where only peak C remains and has increased in area. Peak C
represents the only resulting FA-A2D product.
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Figure 20. Comparison of UV-Vis Spectra: Folic Acid (red), Dopamine (green),
and Initially Proposed FA-A2D (purple)
To further confirm the success of the folic acid A2D linkage, a crude product
sample was submitted for MS (FAB) analysis shown (Figure 8). While the mass
spectrum of the crude product mixture has a large 685 peak, it also shows a small 1108
peak indicating that the desired folic acid amino retinoid compound did indeed form.
The size of the peak in the MS is not considered to be an indication of the amount of
product. A molecule of this size could be easily broken up during bombardment. In
addition, it is typically difficult to visualize folic acid using any form of MS.
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Figure 21. FAB-MS of Crude Folic Acid Dopamine Reaction Products
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MS and HPLC evidence indicated some success with at least partial conversion of
A2D to the folic acid derivative. Unfortunately, however, complete reaction of the
starting material was never achieved and coupling was not consistently reproducible.
There are three possible reasons why the linkage of the pyridinium bis-retinoid to
folic acid was not reproducible and did not go to completion. The first reason is that it
might be sterically difficult for two large molecules to physically come together and form
a tether, slowing the kinetics of the reaction. Second, the length of the linker between
A2D and folic acid may not have been long enough, possibly causing steric problems
after bond formation and making the FA-A2D unusually susceptible to hydrolysis.
Finally, the ester bond might not have been a strong enough bond under these conditions.
Perhaps only an amide bond will be strong enough to hold these two large molecules
together. Further investigation is warranted to determine the cause of reaction failure.
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CHAPTER 4. STUDIES OF PYRIDINIUM BIS-RETINOID A2-CADAVERINE
The next biogenic amine of choice for our pyridinium bis-retinoid library was the
diamine cadaverine (36, Figure 1). A diamine was selected in order to help decipher why
the coupling of folic acid to A2D failed. A diamine would enable an amide bond with
folic acid which would be stronger than the ester linkage made with A2D. In addition,
cadaverine was specifically chosen for its 5 carbon linker that would provide steric relief
between the large pyridinium bis-retinoid and folic acid. With these two variables
changed, we could determine if it was possible to directly link folic acid to a pyridinium
bis-retinoid. Ultimately, the efficacy of our targeted and triggered cancer drug delivery
system depends on the success of the coupling of folic acid to one of our anti-cancer
compounds. Not only could cadaverine solve the folic acid linking problem, but A2cadaverine (A2C) is also suspected to be one of the novel pyridinium bis-retinoids found
in the human eye extractions, based on preliminary MS studies. Thus, two long term
goals of our research can be accomplished.

NH2

H2N

Figure 22. Cadaverine (36)
4.1 Synthesis of A2-Cadaverine
A biomimetic approach was once again chosen for the synthesis of A2C for the
same reasons as listed for A2D. The biomimetic synthesis is an easy one pot reaction
compared to a ten step total synthesis. Also, the biomimetic approach is generally more
economical than a total synthesis of pyridinium bis-retinoids. Accordingly, the starting
material all-trans retinal was synthesized in the same manner as previously reported
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(Chapter 3, Scheme 1). The biomimetic method of choice, however, did differ from that
used to synthesize A2D. The Parish1 method was used to make A2C, in which all-trans
retinal (2) and cadaverine (36) were combined in ethanol and acetic acid. Pezzella’s2
more physiological method was forgone because the formation of a Pictet Spengler
product wasn’t a possibility, and the Parish method was simpler and more
straightforward. The synthesis of A2C (37) is shown in Scheme 1.

N

NH2

O
all-trans Retinal (2)

A2C (37)
AcOH
EtOH

H2N

NH2

Cadaverine (36)

N

N
A4C (38)

Scheme 6. Synthesis of A2C (37)
While cadaverine does not have an electron rich phenyl group to produce an
alternate Pictet Spengler product like dopamine, it is a diamine and can therefore
potentially react with four molecules of all-trans retinal to form the tetra-retinoid A4C
(38). Though A2C and A4C are interesting both as potential anti-cancer agents and toxic
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retinoids implicated in AMD, we initially chose to simplify by using one equivalent of
all-trans retinal to avoid the formation of A4C. Diamines had not previously been used
in this type of synthesis and presented added purification challenges.
One equivalent of all-trans retinal was combined with one equivalent of
cadaverine and acetic acid in ethanol. The reaction was stirred in a dark sealed round
bottom flask for two days. The crude A2C was then purified by column chromatography
using varying concentrations of MeOH, methylene chloride (CH2Cl2), and trifluoroacetic
acid (TFA). The isolated A2C was repurified by chromatotron and recovered in 5 %
yield. UV-Vis spectroscopy, HR-ESI-MS, and proton and carbon NMRs confirmed the
identity of the pure (≈ 92%) A2C. Carbon NMR indicated that the trifluoroacetate anion
(δ 116.3, 162 ppm) was the counterion to A2C.
Five percent was a surprisingly low yield for the A2C compound, even for using
only one equivalent of all-trans retinal. Once A2C had been successfully isolated and
purified, we could experiment with reaction variables to find conditions that would
optimize the yield. The number of equivalents of all-trans retinal was the first condition
to be varied, followed by the number of equivalents of acetic acid, and then the reaction
time. Table 1 shows a comparison of the different conditions attempted and the yields
obtained.
Table 1. Comparison of A2C (37) Reaction Conditions and Yields
Reaction

all-trans Retinal (eq.)

Acetic Acid (eq.)

Time (hours)

Yield

A.

1

1

48

5%

B.

2

1

48

2%

C.

1

1.5

48

11 %

D.

1

1

60

7%

E.

1

1.5

60

12 %
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The first variation to the synthesis was to increase the equivalents of all-trans
retinal from one to two. However, in reaction B, as shown in Table 1, the yield actually
decreased from five to two percent. This made little sense because the synthesis of any
amino bis-retinoid compound requires two equivalents of all-trans retinal and initially
only one was used (reaction A). Because poor yields were obtained when two
equivalents of all-trans retinal were used, only one equivalent was used in future
reactions.
The second variable altered in the synthesis of A2C was the amount of acetic
acid. Acetic acid was only increased by fifty percent in reaction C to one and a half
equivalents. Reasoning for the conservative increase in acetic acid was that Parish1
reported the one-step preparation of A2E to be very sensitive to the overall pH of the
mixture. With this said, it was anticipated that because cadaverine is more basic than
ethanolamine that it would tolerate an increase in acid. The assumption was correct and
the additional acid more than doubled the amount of A2C recovered.
Encouraged by the improved yields, the final control variable altered was the
reaction time. There was a delicate balance in deciding how much to increase the
reaction length. Increased reaction time should theoretically lead to more product.
However, the longer reaction time would also lead to additional isomerization and
decomposition of the products and starting material all-trans retinal. It was decided that
an additional twelve hours of stirring would lead to higher A2C yields while minimizing
the amount of isomerization and decomposition. Reactions D and E were both stirred for
60 hours and trial E was used to test the effect of the extra 0.5 equivalent of acetic acid.
As reported in Table 1 both reactions, D and E, showed an increased yield compared to
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their 48 hour counterparts. Reaction D, in which one equivalent of acetic acid was used,
resulted in an increase from five to seven percent versus Reaction A. However, in
Reaction E (1.5 equivalents of AcOH) only a slight increase in yield was observed of
twelve percent compared to Reaction C’s eleven percent A2C recovery.
Overall, it was determined that using one and a half equivalents of acetic acid and
stirring for 48 hours produced A2C with the best purity and yield. It was surprising to
discovery that increasing the amount of all-trans retinal from one equivalent to the
required two (compared to one equivalent of cadaverine) actually had an ill effect on the
yield. Perhaps this can be attributed to the formation of the A4C product. However,
evidence for the formation of the A4C product was never found during mass
spectrometry analysis of crude aliquots. Of course the A4C product, due to its large size,
could easily be broken up during mass spectrometry and never be detected. An
additional explanation for poor yields is that cadaverine’s second amine is far more
nucleophilic than ethanolamine’s hydroxyl group and thus can alternatively form various
Schiff base products instead of the desired pyridinium bis-retinoids.
Unlike the two equivalents of all-trans retinal, the added acid yielded better than
expected results. There are two possible explanations for this phenomenon. First, acid
was added in the initial A2E reaction to serve as a catalyst. Cadaverine is basic and
therefore tolerated the extra acid better, which led to an increase in reaction rate. The
second explanation is that the added acid rendered the primary amine on A2C less
nucleophilic, and therefore less likely to form unwanted side products. While the
biomimetic synthesis of A2C might not have produced good yields, it was the simplest
method for our purposes.

60

4.2 A2C Photochemical Experiments
The next step in determining whether A2C may be cytotoxic was to test the
isolated A2C for potential photoreactivity. If A2C is a major cytotoxin in the RPE, then
it will likely be through photochemical mechanisms. Moreover, if biogenic diamines
prove to be the best option for tethering bis-retinoids to folic acid, then they too must
have A2E’s capability to generate photooxidation products in order for our cancer
treatment to be viable.
The photooxidation of the diamine bis-retinoid A2C was carried out by dissolving
the pure compound in a ten percent DMSO solution. A two sided polystyrene visible
cuvette filled with the dissolved A2C was irradiated with light using a 442 nm
interference filter. Aliquots of the irradiated compound were taken once every hour for
five hours and analyzed by HPLC and ESI-MS. Figure 2 shows a picture of the setup
used in the pyridinium bis-retinoid irradiation experiments.

Figure 23. Photochemical Experiment Setup
The HPLC and ESI-MS results are illustrated in Figures 3 and 4 for samples taken
at zero, one, three, and five hours of irradiation. From the first HPLC chromatogram in
Figure 3 before irradiation has commenced, one can see a single clean A2C (A) peak with
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minor isomer products. After exposure to blue light for one hour there is an emergence
of two peaks (B and C) in addition to A2C (A). Corresponding UV-Vis spectra indicate
that peak C is not significantly blue shifted and is a result of the expected
photoisomerization. Its UV-Vis spectrum resembles the typical 13-cis isomer of A2E
and suggests that peak C may be the 13-cis isomer of A2C, which assumes a steady state
ratio with all-trans A2C throughout the remaining irradiation. Peak B has an interesting
corresponding UV-Vis spectrum that is blue shifted nearly 35 nm compared to that of
peak A, indicating loss of conjugation and reaction at a double bond. In addition to
having an interesting UV-Vis, peak B also has a shorter retention time than A2C on
reversed phase HPLC, meaning that this new photo product is more polar than its
predecessor.
The most dramatic change in HPLC evidence occurs between one and three hours
of irradiation time. According to the three hour chromatogram, the initial photoproduct
(peak B) has almost doubled its area, while the A2C peak has suffered a significant loss.
In addition to the drastic change in A and B peak ratios, two new non-oxidative product
peaks have appeared, suggesting decomposition or isomerization due to light. The final
HPLC chromatogram observed after five hours of irradiation demonstrates the extent to
which photo reactivity occurs. The starting bis-retinoid (peak A) has been almost
completely consumed, leaving only various photo, isomer, and side products. Even the
blue shifted product (peak B) is no longer the dominant peak.
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Figure 24. A2C Photochemistry HPLC Chromatograms at 0, 1, 3, and 5 Hours
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Figure 25. A2C Light Experiment ESI-MS Results for 0, 1, 3, and 5 Hours
The MS results in Figure 4 echo that observed on HPLC chromatograms. Starting
after one hour of irradiation there is an emergence of a product peak of m/z 649, differing
from the M+ by m/z 16. This new peak visualized in MS correlates to the appearance of
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the HPLC photo-product having a shorter retention time and blue shifted UV-Vis
spectrum. MS and HPLC evidence combined suggest that this new product is a result of
the addition of oxygen to the double bonds on the longer retinoid arm of A2C. Thus, the
hypsochromic UV-Vis shift is due to loss of conjugation, and the shorter retention time is
a consequence of increased polarity from the added oxygen.
Similar to that seen in the HPLC chromatograms, the most radical change in
solution composition according to MS occurs between one and three hours of irradiation.
Not only is there a complete reversal in the m/z 633 and m/z 649 peak ratios, indicating a
loss of A2C, but two new oxidation products appear at m/z 665 and m/z 683 . The m/z
665 is exactly 32 mass units greater than the starting material A2C, corresponding to the
addition of two oxygens. The second product peak at m/z 683 is 50 atomic mass units
greater than A2C, and 2 mass units larger than the expected tris-oxo peak of m/z 681,
suggesting insertion of three oxygens and two additional hydrogens.
Finally, after five hours of light exposure we once again observe further decrease
in the parent A2C ion, almost to complete extinction, and an increase of photooxidation
products, including a new peak at m/z 699. Interestingly, the new m/z 699 product peak
is exactly 16 atomic mass units greater than the 683 peak at three hours of irradiation,
suggesting the addition of just one oxygen atom to the third photooxidation product. In
addition to the disappearance of the A2C parent ion and the new observed oxidation
peak, one can also observe the formation of up to five more minor oxidation peaks in
increments of m/z + 16. This makes a total of nine photooxidation products, with up to
nine oxygens incorporated into the bis-retinoid arms.
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Likewise, A2E has also been shown to generate nine photooxidation products by
MS.3 As discussed in Chapter 3 it was recently suggested that A2E epoxidation begins at
the 5,6 double bond of amino bis-retinoids, and in some cases rearranges to form a 5,8furanoid product.4,5 Also, it was found that the more highly oxygenated bis-retinoid
products are likely polyperoxide species resulting from a [4+2] cycloaddition with singlet
oxygen.5 Based on this information, we conclude that the observed oxo-A2C products
are similar to those observed with A2D and are also a consequence of epoxidation and
[4+2] cycloadditions with singlet oxygen.
While A2C did show extensive photoreactivity similar to A2E, it did differ in the
most abundant species formed. Typically, the most dominant A2E photoproduct
observed incorporates two oxygen atoms, but as seen by HPLC evidence in Figure 3 and
MS in Figure 4, the most abundant is the mono-oxygenated A2C product.3,5 Even though
A2C does not appear to generate the bis-oxo as the main oxidation product, it does
generate polyoxidative species, which should be cytotoxic based on A2E literature
precedence.
In addition to the multiple photooxidation products evidenced by MS, there are
also other unknown products observed in HPLC, namely peaks D and E in Figure 3. The
UV-Vis spectra corresponding to peaks D and E do not exhibit the classic 40 nm
hypsochromic shift seen in oxidized pyridinium bis-retinoids. However, these
unaccounted peaks could easily arise from isomerization or a reaction between an
unstable oxidation product and a nucleophile, such as the amine from cadaverine.
Another incongruency between A2E and A2C found through HPLC analysis is that the
most common site for oxidation of A2E is on the short retinoid arm. However, from peak
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B’s corresponding UV-Vis spectrum one can see that the preferred oxidation site of A2C
is on the longer retinoid arm. This is concluded because A2C’s λmax is shifted from 444
to 411 as compared to the shift from 337 to 297 observed with oxo- A2E.4 The structure
of the oxo-A2C products have not been determined by NMR data and are speculative
based on the current literature. However, for our purpose it was only necessary to
demonstrate similar potential photooxidation capabilities of A2C.

4.3 Coupling of Folic Acid to A2C
Once A2-Cadaverine’s potential phototoxicity had been confirmed, the ultimate
test of our proposed targeted and triggered cancer drug therapy came down to coupling
folic acid with the synthesized A2C. Other attempts in our lab at tethering pyridinium
bis-retinoids to folic acid had failed. It was essential for the diamine bis-retinoid, A2C, to
form the desired folic acid-A2-cadaverine (FA-A2C) product for our proposed
chemotherapy system to be viable. The approach used to obtain the folic acid product
was the same standard coupling conditions, shown in Scheme 2, used in the FA-A2D
synthesis. Once again, folic acid’s α and γ carboxylic acid groups were not selectively
protected because the purpose of this initial attempt was to see if a connection between
folic acid and A2C was possible.
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Scheme 7. Reaction of Folic Acid and A2C
Folic acid was first activated with DCC, stirred in dark and dry conditions for six
hours. Following this, A2C and DMAP were dissolved in DMSO and transferred via
syringe to the activated folic acid. The reaction was stirred for 15 hours and progress was
tracked by HPLC. The A2C and folic acid reaction was successful. HPLC analysis
(Figure 5) revealed the formation of two major products nearly equal in area with almost
identical retention times and UV-Vis spectra. These major products were accompanied
by two minor products also equal in area with similar, yet slightly blue shifted, UV-Vis
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spectra. The four new peaks’ corresponding UV-Vis spectra appeared to be a
combination of folic acid and A2C, similar to that observed in the A2D coupling. Figure
6 shows the combination UV-Vis spectra belonging to the two main products, along with
the UV-Vis spectra of the starting materials (folic acid and A2C). From the two identical
UV-Vis spectra the main product peaks were believed to be a result of the formation of αFA-A2C (39) and γ-FA-A2C (40) products. Logically, the two minor product peaks were
assigned to be the 13-cis isomers of the α and γ tethered A2C derivatives.
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Figure 26. FA-A2C Reaction HPLC Chromatogram and
Corresponding UV-Vis Spectra
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Figure 27. Comparison of Folic Acid (red), A2C
(blue), and FA-A2C (green) UV-Vis Spectra
Not only did HPLC tracking reveal reaction success, but it also proved that the
products were stable and did not mysteriously disappear or revert back to starting
material over time, a common problem with A2D and other pyridinium bis-retinoids.
After 15 hours of stirring, the reaction was quenched with chilled distilled water. Upon
the addition of water, a red crystalline-like precipitate formed. The precipitate was
subsequently collected, filtered, washed with water, methanol, ether, and finally
dissolved in a 5:95 MeOH/CH2Cl2 solution. Working with the desired FA-A2C product
revealed that it was stable enough to be chromatographed multiple times. The folic acid
targeted compound was first purified by column chromatography using CH2Cl2 with five
percent MeOH followed by increasing concentrations of MeOH in CH2Cl2. The coveted
folic acid A2C material was obtained with a 20:80:0.005 MeOH/CH2Cl2/TFA solution.
Both 1H NMR and ESI-MS confirmed the successful formation and isolation of the folic
acid linked A2C drug. As seen with the FA-A2C UV-Vis spectra, the 1H NMR also
appeared to be a combination of both folic acid and A2C proton NMRs. Proton NMR
also showed the α and γ folic acid labeled compounds to be recovered with reasonable
purity for a combined yield of 75 %. From this point the two FA-A2C products could be
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further separated into the α and γ counterparts by chromatotron using a 25:75
MeOH/CH2Cl2 solution. However, while separation was possible, it usually came at a
high price of decreased yields.
The addition of folic acid to a pyridinium bis-retinoid is a significant chemical
derivatization and it was unknown how this change would affect the photochemical
characteristics of A2C. The added folic acid could potentially quench excited states,
provide new oxidative sites, or cause no significant change at all. Consequently,
preliminary photochemistry experiments were commenced on the combined α and γ FAA2C products. Irradiation was conducted under the same conditions used for the
photooxidation of A2C. The material was dissolved in a DMSO/H2O solution and
irradiated with a 442 nm interference filter in a two sided polystyrene visible cuvette.
Aliquots of the blue light irradiated sample were taken for HPLC and MS analysis.
Surprisingly, after just one hour of blue light exposure there was not any original FAA2C remaining according to HPLC or ESI-MS results. Only unrecognizable
photoproducts remained in solution. Figure 7 shows a comparison between FA-A2C
stock solution and the FA-A2C sample after one hour of irradiation. From the
photograph one can observe a significant change in color from bright orange to pale
yellow after one hour of blue light exposure, indicating that extensive photobleaching has
occurred.
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Figure 28. Before and After Irradiation of FA-A2C with Blue Light

It appears from photochemistry experiments that the FA-A2C derivative is
substantially more light sensitive than the original A2C molecule. Even exposure to
ambient light seems to induce photooxidation. Figure 8 shows a comparison of two UVVis spectra resulting from an FA-A2C solution exposed to small amounts of ambient
light. The blue spectrum corresponds to the FA-A2C. The red spectrum is similar in
shape to the blue, but shows a large characteristic hypsochromic shift from 440 to 416 nm
and is believed to be the result of a photooxidation FA-A2C product. Similar to that
observed with A2C, oxidation also seems to occur on the long retinoid arm of FA-A2C.
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Photoproduct (red)
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In conclusion, the synthesis and isolation of the folic acid tethered pyridinium bisretinoid, FA-A2C, was a success. We demonstrated that the direct linkage of folic acid to
a pyridinium bis-retinoid in a one pot process was in fact possible and the products were
attainable in good yields, proving that there was hope for our targeted and triggered
cancer drug delivery system. Not only was the FA-A2C product easily isolated, but the α
and γ tethered products could also be separated by chromatotron, eliminating the extra
steps involved with selectively protecting the carboxylic acids. Unfortunately, the
current separation procedure returns the α and γ products in low yields, but refinement of
the procedure should improve the quantities recovered. Attempts will not be made to
selectively protect the α or γ carboxylic acid groups of folic acid. Not only does this
eliminate unnecessary steps, but both products are also biologically interesting for
cellular assays.
Additionally, it was found that FA-A2C was exceptionally stable at room
temperature and could be chromatographed multiple times with minimal decomposition.
The stability of this folic acid tethered pyridinium bis-retinoid suggests that other folic
acid labeled drugs from our pyridinium bis-retinoid library might also be stable and could
be simply purified by column chromatography. It remains to be determined why the
reaction between folic acid and A2C was a success, while the reaction with A2D failed.
The success may have been a result of the added stability of the amide bond compared to
a weaker FA-A2D ester bond. Success may have also been made possible by the relief of
steric congestion provided by cadaverine’s five carbon linker between folic acid and the
pyridinium bis-retinoid, or perhaps a combination of both variables could have been the
cause of success. Further investigation into this matter is currently underway.

73

Finally, preliminary photochemistry experiments suggest that FA-A2C may be a
more potent phototoxin than A2C. This was an unexpected, yet fortuitous outcome. It
was initially anticipated that because folic acid is a vitamin and had been reported to have
some antioxidative capabilities that it was going to deleteriously alter the photochemical
properties of A2C.6 However, FA-A2C was completely destroyed after one hour of
irradiation with blue light. Also, it appeared that photooxidation could be induced even
from ambient light. A possible explanation for this phenomenon has recently been
proposed by Jakus et al.7 wherein they relate that some antioxidants exhibit pro-oxidant
activity when combined with photodynamic therapy. The authors speculate that the
addition of antioxidants onto sensitizer molecules could provide effective new cancer
treatments.
Another likely cause of the observed photochemical reactivity is that folic acid is
known to decompose upon exposure to light and it has been reported that singlet oxygen
may participate in this mechanism.8,9 Perhaps the photosensitivity of folic acid and A2C
synergistically combine to produce singlet oxygen which subsequently reacts with A2C
to form various photooxidation products. Additional experimentation with shorter and
less intense irradiation intervals is needed to determine the mechanism and products
involved in photodegradation. If the hypothesis that A2C and folic acid synergistically
produce singlet oxygen is true, then the FA-A2C derivative could be a cytotoxin. This
fortuitous outcome could potentially mean less drug, light intensity, and exposure time
necessary to induce apoptosis and eventually an all-around less invasive cancer treatment.
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CHAPTER 5. FUTURE WORK AND CONCLUSIONS
5.1 Identification of New Pyridinium Bis-Retinoids in Human RPE
We have observed new putative pyridinium bis-retinoids in melanolipofuscin and
human RPE eye extracts. These have yet to be identified due to the small quantities of
material. However, it is known from HPLC analysis that these unidentified compounds
are more polar than A2E and this information has provided a general direction from
which to continue the investigation. Eldred1 initially used 250 human donor eyes which
provided 100 micrograms of material for the elucidation of A2E. Similarly, it will
require a large amount of material to identify other pyridinium bis-retinoids. The
extraction procedure will be scaled up to accommodate at least a hundred donor eyes.
The most promising method for the identification of these new compounds will be the use
of LC-MS wherein the compound’s UV-Vis spectrum can be obtained simultaneously
with the high resolution m/z and molecular formula. From this point, standards can be
used for further structural elucidation, opening the door to additional photophysical,
chemical, and toxicity studies in relation to lipofuscin and AMD.
We have also begun the construction of our pyridinium bis-retinoid library for
the purpose of identifying the unknown compounds found in the eye. We have
successfully synthesized, isolated, and characterized the pyridinium bis-retinoids A2C
and A2D, and plan to continue expanding the selection of amino bis-retinoid standards.
Unfortunately, neither A2D nor A2C have yet been identified as the novel eye
compounds, but we are still pursuing this. Another promising pyridinium bis-retinoid to
consider for our library is A2-Serine (Figure 1, 41). The biosynthesis of A2E involves
the condensation of all-trans retinal with phosphatidylethanolamine,2,3 one of the most
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prominent lipids in photoreceptor cells. Another abundant lipid present in photoreceptor
cells, though four times less common than phosphatidylethanolamine (42), is
phosphatidylserine.4,5 All-trans retinal would likely react with phosphatidylserine within
the photoreceptor membrane eventually resulting in A2-serine. This reaction is not only
a plausible outcome, but it would also result in a pyridinium bis-retinoid compound that
would be more polar than A2E, corresponding to that observed in the HPLC analysis of
eye extracts.
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Figure 30. Potential Biogenic Amine and Corresponding Pyridinium Bis-Retinoid

5.2 Additional Development of a Targeted and Triggered Cancer Treatment
While A2D and A2C have not yet been identified as the new pyridinium bisretinoid present in human eye extractions, they may fulfill a second purpose: the
development of our targeted and triggered drug delivery system. We attempted to tether
folic acid to A2D through an ester bond, but the results were not reproducible. We next
moved to A2C as a potential cancer therapeutic. The coupling of folic acid to A2C was a
success and the product was isolated through column chromatography in good yields.
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Both α-FA-A2C and γ-FA-A2C (Figure 2, 39 and 40) products formed and were
separated via chromatotron. However, the yields diminished significantly upon isolation.
One of our immediate concerns is to improve the isolation method of the α and γ
products. From this point several projects will arise. For instance, competition assays
need to be performed to prove that the folic acid labeled derivatives are uptaken
preferentially to the original A2C. This will be done by incubating cancer cells with folic
acid, A2C, α-FA-A2C and γ-FA-A2C. The corresponding cells will then be extracted
using the human RPE extraction protocol and the amount of compound present quantified
by HPLC. These experiments are underway in our laboratory.
Also, preliminary photochemistry experiments suggested that FA-A2C could be a
more potent phototoxin than originally anticipated. Additional irradiation experiments
will be executed to confirm this hypothesis wherein the duration of light exposure will be
shortened. Instead of samples taken over a five hour period, aliquots will be taken every
ten minutes for one hour. Finally, once potential photooxidation has been demonstrated,
cancer cell assays will be conducted comparing the efficiency of A2C, α-FA-A2C and γFA-A2C at inducing apoptosis. Cells will be incubated with either A2C, α-FA-A2C, γFA-A2C, folic acid, or culture media and then subsequently irradiated with blue light.
Controls wells will be used and include the same components mentioned, with the
exception that these cells will be kept in the dark. Cell viability will be assessed 24 hours
post irradiation. These experiments are also underway in our laboratory.
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5.3 Conclusion
In summary, through melanolipofuscin and human RPE eye extractions, we have
observed putative new pyridinium bis-retinoids, which may play a role in the etiology of
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age-related macular degeneration. In order to characterize these observed biological
compounds we have begun to create an amino-retinoid library by synthesizing A2D and
A2C. As our library has a dual purpose, these two pyridinium bis-retinoids were also
reacted with folic acid in an attempt to create a targeted and triggered cancer treatment.
While the isolation of FA-A2D failed, the reaction with A2C was successful.
Additionally, preliminary photochemical experiments suggest that FA-A2C is
substantially more photoreactive than A2C. This surprising discovery could potentially
lead to less drug, light, and exposure time required to induce cancer cell death, and an
overall less toxic and invasive treatment for cancer patients.

5.4 References
1. Eldred, G. E.; Lasky, M. R. Nature 1993, 361, 724–726.
2. Mata, N. L.; Weng, J.; Travis, G. H. Proc. Natl. Acad. Sci. USA 2000, 97, 7154–
7159.
3. Liu, J.; Itagaki, Y.; Ben-Shabat, S.; Nakanishi, K.; Sparrow, J. R. J. Biol. Chem.
2000, 275, 29354–29360.
4. Anderson, R. E.; Maude, M. B. Biochemistry 1970, 9, 3624–3628.
5. Shichi, H. Biochemistry of Vision 1983, pp. 122–142, Academic Press, New York.

80

CHAPTER 6. EXPERIMENTAL AND SPECTROSCOPIC DATA
6.1 General Methods
DMSO was dried via a solvent drying system using activated alumina. All other
solvents and materials were obtained from Fluka or Aldrich and used as purchased,
unless otherwise indicated. All extractions and reactions were performed in the dark at
room temperature. Column chromatography was carried out using Sorbent Technologies
40-63 μm silica gel. HPLC and UV-Vis data were obtained on a Waters 600 HPLC
system equipped with either a Cosmosil Packed Column 5C18-P-MS 4.6 x 250 mm or
Phenomenex Synergi Max 250 x 4 mm column as indicated, with a Waters 2998
photodiode array detector. Chromatographic solvents were HPLC grade H2O with 0.1%
TFA and acetonitrile (ACN). MS data was obtained on an Agilent Technologies
Multimode Electrospray APCI mass spectrometer running in ES+APCI+mode. 1H NMR
spectra were obtained on a Varian Unity Inova 500 MHz spectrometer using
tetramethylsilane (0.00 ppm) as an internal reference. Signals are reported as follows, s
(singlet), d (doublet), t (triplet), q (quartet), quin (quintet), dd (doublet of doublets), dt
(doublet of triplets), bs (broad singlet), m (multiplet). Coupling constants are reported in
hertz (Hz).

13

C NMR spectra were obtained on the Varian spectrometer operating at 125

MHz, with tetramethylsilane as an internal standard.

6.2 Extraction Procedure Experimental Details
Human RPE were obtained from the Utah Lion’s Eye bank and provided by Dr.
Paul Bernstein of the Moran Eye Institute in Salt Lake City, UT. Lipofuscin and
melanolipofuscin preparations were provided by Dr. Craig Thulin of Brigham Young

81

University (currently at Utah Valley State College). Lipofuscin, melanolipofuscin, and
donor RPE were stored at -80 °C until extracted. None of the RPE or eyes used for
lipofuscin and melanolipofuscin preparations had an ophthalmologic history.
To a homogenizer were added human RPE, lipofuscin, or melanolipofuscin in 1:1
CHCl3/MeOH (2 mL) and 0.01 M phosphate buffered saline (PBS) (1 mL). RPE tissues,
lipofuscin, or melanolipofuscin were homogenized in a Kimble-Kontes Tenbroeck tissue
grinder. The homogenate was transferred to the appropriate sized separatory funnel. The
tissue grinder was rinsed with 1:1 CHCl3/MeOH (2 mL) and 0.01 M PBS (1 mL),
followed by CHCl3 ( 5 mL) and CH2Cl2 (5 mL). Rinses were added to the separatory
funnel. The organic layer was collected and the aqueous phase extracted 3 times with 1:1
CHCl3/CH2Cl2 (10 mL). The combined organic extracts were dried over anhydrous
sodium sulfate, concentrated in vacuo, and loaded onto a cotton and C18 silica gel pipette
column system. The material was eluted with 0.1% TFA in MeOH. The collection was
concentrated in vacuo and dissolved in a minimal amount of 1:1.5 MeOH/CH2Cl2 for
HPLC analysis. Aliquots were examined by HPLC (Cosmosil Packed Column 5C18-PMS 4.6 x 250 mm) running a gradient from 16% H2O in ACN with 0.5% TFA to 100%
ACN with 0.5% TFA.
Sample runs were examined for retinal, retinol, A2E, iso-A2E, and other
pyridinium bis-retinoid compounds. In human RPE, A2E and iso-A2E were found at
approximately 13.0 and 14.2 minutes, respectively. A peak at 8 minutes showed UV-Vis
absorbances at λmax 329 nm and 432 nm. A2E and isomers were found in
melanolipofuscin by UV-Vis at approximately 10.3 and 10.7 minutes for A2E and isoA2E, respectively. Peaks were found at 8.6 and 9.0 minutes with λmax 341.0 nm, 433.2
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nm and 339.8 nm, 430.8 nm, respectively. Human RPE. A2E: UV-Vis: λmax 337.4 nm,
445 nm (lit. 336 nm, 439 nm, MeOH)1, Iso A2E: UV-Vis: λmax 331.5 nm, 433.2 nm (lit.
335 nm, 430 nm, MeOH).1 Melanolipofuscin. A2E: UV-Vis: λmax 339.8 nm, 433.2 nm
(lit. 334 nm, 439 nm, MeOH)1, Iso A2E: UV-Vis: λmax 331.5 nm, 423.5 nm (lit. 335 nm,
430 nm, MeOH).1

6.3 Synthesis Experimental Details

OH

(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8tetraen-1-ol, all-trans retinol (5).2 To a solution of vitamin A propionate (22, 6.71 g,
19.6 mmol) in MeOH (20 mL) and THF (2 mL) was added K2CO3 (3.29 g, 23.8 mmol).
The solution was stirred in the dark at room temperature for four hours. To this solution
was added 1:1 hexanes/Et2O (100 mL). The resulting unwanted solid was removed by
filtration and the product was concentrated in vacuo. The residue was purified by
chromatography (SiO2, 10% EtOAc in hexanes) to give 5 (4.49 g, 15.7 mmol, 80%) as a
yellow oil.

O

(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8tetraenal, all-trans retinal (2).3 To a solution of all-trans retinol (5, 4.49 g, 15.7 mmol)
in CH2Cl2 (50 mL) was added MnO2 (20.3 g, 223 mmol). The reaction was stirred in the
dark at room temperature for 5 hours and then the excess MnO2 was removed by
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filtration through celite. The product was concentrated in vacuo and the residue purified
by chromatography (SiO2, 3% EtOAc in hexanes) to give a yellow oil. Chilling and
addition of hexanes (5 μL) to the product yielded 2 (3.82 g, 13.4 mmol, 85%) as an
orange crystal.
Dopamine Reaction Study. Method I, Reaction I. To a solution of all-trans
retinal (2, 0.0580 g, 0.204 mmol) in ethanol (3 mL) were added dopamine hydrochloride
(21, 0.0331 g, 0.175 mmol) and acetic acid (10.5μL). The resulting solution was stirred
for 48 hours in the dark. The crude reaction mixture was analyzed using FAB techniques
with an NBA matrix. A1D (26, 26) LRMS (FAB) m/z 420.
Method I, Reaction II. To a solution of all-trans retinal (2, 0.0579 g, 0.204 mmol)
in ethanol (3 mL) was added dopamine hydrochloride (21, 0.0335 g, 0.177 mmol). The
resulting solution was stirred for 48 hours in the dark. The crude reaction mixture was
analyzed using FAB techniques with an NMB matrix. A1D (26, 27) LRMS (FAB) m/z
420.
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2-[2,6-Dimethyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl-)-1E,3E,5E,7Eoctatetraenyl-1-(3,4-dihydroxyphenyl)-4-[4-methyl-6-(2,6,6,-trimethyl-1-cyclohexen1-yl)-1E,3E,5E-hexatrienyl]-pyridinium dodecyl sulfate (A2-dopamine, A2D, 25).
Method II. To a solution of all-trans retinal (2, 0.0598 g, 0.210 mmol) in 0.1 M
phosphate buffer, pH 7.4, with 1.5 % w/w SDS (9 mL) was added dopamine
hydrochloride (21, 0.0333 g, 0.176 mmol). The reaction was stirred in the dark with a
sealed cap for 48 hours and the aqueous layer was extracted with CH2Cl2 (5 x 10 mL).
The combined organic extracts were concentrated in vacuo. Purification of the residue by
chromatography (SiO2, 0-5% MeOH in CH2Cl2 gradient elution), followed by
chromatotron (5% MeOH in CH2Cl2) to yield 25 (0.0199 g, 0.0210 mmol, 20%) as a red
solid: 1H NMR (CDCl3, 500 MHz) δ 0.88 (DS: 3H, t, J = 6.75, CH3), 1.05 (12H, s, 4 x
CH3) 1.25 (DS: 18H, m, 9 x CH2), 1.39 (DS: 2H, m, CH2), 1.49 (4H, m, 2 x CH2), 1.63 (4
H, m, 2 x CH2), 1.71 (3H, m, C=CCH3), 1.74 (3H, s, C=CCH3), 2.05(4H, s, 2 x
C=CCH3), 2.05 (3H, s, C=CCH3), 2.11 (3H, s, C=CCH3), 2.12 (3H, s, C=CCH3), 2.97
(2H, bs, CH2Ar), 4.12 (DS: 2H, bs, CH2OSO3), 4.17 (2H, bs, CH2N), 6.07 (1H, s,
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HC=C), 6.08 (1H, s, HC=C), 6.18-6.25 (4H, m, HC=C), 6.28 (1H, s, ArH), 6.33 (1H, s,
ArH), 6.37 (1H, d, J = 6.0, ArH), 6.42 (1H, d, J =15, HC=C), 6.50 (1H, s, HC=C), 6.54
(1H, s, HC=C), 6.62 (1H, d, J = 7.5, HC=C), 7.02 (1 H, dd, J =11.5, 14.5, HC=C), 7.51
(1H, bs, pyrArH), 7.62 (1H, dd, J = 12.0, 14.5, pyrArH), 8.57 (1H, bs, pyrArH); 13C
NMR (CDCl3, 125 MHz) δ 13.15-39.87 (30C, 10 x CH3, 18 x CH2, 2 x C(CH3)2), 58.180
(CH2N), 68.30 (CH2OSO3), 114.51-152.55 (29C, 18 x C=C, 11 x ArC); UV-Vis (CH2Cl2)
λmax 342.2 nm, 438.0 nm; HRMS (ESI+) m/z 684.4785 (M+, C48H62NO2 requires
684.4781).
A2D Photochemical Experiments. To a vial of DMSO (2 mL) was added A2D
(0.0070 g) and H2O (18 mL). A sample of the resulting solution (4 mL) was placed in a
two sided, 10 mm, polystyrene vis-cuvette. The cuvette was irradiated with blue light
(dichroic blue filter, 400-500 nm). Aliquots of the sample (100 μL) were taken for ESIMS analysis every hour for five hours.
Folate A2-dopamine (FA-A2D). To an oven dried round bottom flask were
added folic acid (20, 0.0653 g, 0.148 mmol), 1,3-dicyclohexylcarbodiimide (DCC)
(0.0805 g, 0.390 mmol), and DMSO (3 mL). The resulting mixture was stirred in the
dark under N2 for 12 hours. To this flask via syringe was added A2D (25, 0.0200 g,
0.0211 mmol) and 4-dimethylaminopyridine (DMAP) (0.0286 g, 0.234 mmol) in DMSO
(3 mL). The combined reaction mixture was stirred in the dark under N2 for 24 hours.
Aliquots were taken at 5 minutes and 24 hours of reaction time for analysis via HPLC
(Phenomenex Synergi Max column, 250 x 4.0 mm) using a gradient from 90% H2O with
0.1% TFA in ACN to 100% ACN. Partial conversion to the presumed product was
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observed at 24 hours. UV-Vis (DMSO) λmax 302.9 nm, 343.4 nm, 445.2 nm; LRMS
(FAB) m/z 1108.

O
O
N

CF3
NH2

2-[2,6-Dimethyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl-)-1E,3E,5E,7Eoctatetraenyl-1-(5-aminopentyl)-4-[4-methyl-6-(2,6,6,-trimethyl-1-cyclohexen-1-yl)1E,3E,5E-hexatrienyl]-pyridinium 2,2,2-trifluoroacetate (A2-cadaverine, A2C, 37).
To a solution of all-trans retinal (2, 0.2686 g, 0.9444 mmol) in ethanol (5 mL) was added
cadaverine (36, 0.0922 g, 0.902 mmol ) and acetic acid (54.2 μL, 0.903 mmol), and the
resulting solution was stirred at room temperature in the dark for 48 hours. The solvent
was removed in vacuo, and the residue was purified by column chromatography (SiO2, 040% MeOH in CH2Cl2 gradient, further elution with 40:60:0.005 MeOH:CH2Cl2:TFA),
followed by use of the chromatotron (13% MeOH in CH2Cl2) to afford A2C 37 (0.0388
g, 0.0519 mmol, 11%) as a red solid: 1H NMR (CD3OD, 500 MHz) δ 1.04 (6H, s, 2 x
CH3), 1.05 (6H, s, 2 x CH3), 1.49 (2H, m, CH2), 1.50 (4H, m, 2 x CH2), 1.65 (4H, m, 2 x,
CH2), 1.70 (2H, m, CH2(CH2NH2)), 1.72 (3H, s, C=CCH3), 1.74 (3H, s, C=CCH3), 1.91
(2H, quin, J = 6.3, CH2(CH2N)), 2.03 (3H, s, C=CCH3), 2.05 (4H, m, 2 x C=CCH2), 2.16
(3H, s, C=CCH3), 2.18 (3H, s, C=CCH3), 2.93 (2H, t, J = 7.5, CH2NH2), 3.31 (2H, s,
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NH2), 4.44 (2H, t, J = 7.5, CH2N), 6.18 (1H, d, J = 17.0, C=CH), 6.25 (1H, d, J=10,
C=CH), 6.28 (1H, d, J = 17.0, C=CH), 6.35 (1H, d, J = 15.0, C=CH), 6.42 (1H, d, J =
10.0, C=CH), 6.55 (1H, d, J =15.0, C=CH), 6.65 (1H, d, J =15.0, C=CH), 6.67 (1H, s,
C=CH), 6.76 (1H, d, J =15.0, C=CH), 7.13 (1H, dd, J = 15.1, 11.7, C=CH), 7.86 (1H, s,
ArH), 7.94 (1H, m, ArH), 8.00 (1H, dd, J = 15.1, 11.7, C=CH) 8.61 (1H, d, J = 6.84,
ArH); 13C NMR (CD3OD, 125 MHz) δ 11.77-39.63 (20C, 9 x CH3, 9 x CH2, 2 x
C(CH3)2), ≈47 (CH2NH2), 56.70 (CH2N), 116.3 (CF3), 118.79-153.56 (23C, 18 x C=C, 5
x ArC), 162 (COCF3); UV-Vis (DMSO) λmax 338.6 nm, 444.0 nm; HRMS (ESI+) m/z
633.5148 (M+, C45H65N2 requires 633.5148).
A2C Photochemical Experiments. To a vial of DMSO (2 mL) was added A2C
(0.0047 g) and H2O (18 mL). A sample of the resulting solution (4 mL) was placed in a
two sided, 10 mm, polystyrene vis-cuvette. The cuvette was irradiated with blue light
(442 nm interference filter). Aliquots of the sample (100 μL) were taken for HPLC
analysis (Phenomenex Synergi Max column, 250 x 4.0 mm) running a gradient from 90%
H2O with 0.1% TFA in ACN to 100% ACN and ESI-MS analysis every hour for five
hours.
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1-(5-((S)-2-(4-((2-Amino-4-oxo-3,4-dihydropteridin-6yl)methylamino)benzoamino)-4-carboxybutanamido)pentyl)-2-((1E,3E,5E,7E)-2,6dimethyl-8-(2,6,6-trimethylcyclohex-1-enyl)octa-trimethylcyclohex-1-enyl)hexa1,3,5-trienyl)pyridinium (α-Folic Acid-A2-cadaverine, α-FA-A2C, 39). 1-(5-((S)-4(4-((2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methylamino)benzamido)-489

carboxybutanamido)pentyl)-2-((1E,3E,5E,7E)-2,6-dimethyl-8-(2,6,6trimethylcyclohex-1-enyl)octa-1,3,5,7-tetraenyl)-4-((1E,3E,5E)-4-methyl-6-(2,6,6trimethylcyclohex-1-enyl)hexa-1,3,5-trienyl)pyridinium (γ-Folic Acid-A2cadaverine, γ-FA-A2C, 40). To an oven dried round bottom flask were added folic acid
(20, 0.0630 g, 0.143 mmol), DCC (0.0488 g, 0.237 mmol), and DMSO (5 mL). The
solution was stirred in the dark under N2 at room temperature for 6 hours. To this
reaction via syringe was added A2C (37, 0.0468 g, 0.0626 mmol) and DMAP (0.0074 g,
0.0606 mmol) in DMSO (5 mL). The resulting red solution was stirred at room
temperature under N2 in the dark for 15 hours. The reaction was quenched by addition of
chilled H2O (5 ml) which resulted in the formation of a red precipitate. The solid was
filtered and washed successively with H2O (200 mL), MeOH (10 mL), Et2O (30 mL), and
CH2Cl2 (10 mL). The solid was dissolved with 10% MeOH in CH2Cl2 and concentrated
in vacuo. Purification of the residue by chromatography (SiO2, 5-20% MeOH in CH2Cl2
gradient, further elution with 20:80:0.005 MeOH:CH2Cl2:TFA) gave the combined α and
γ products 39, 40 (0.0541 g, 0.0462 mmol, 74%) as a red solid: 1H NMR (d6-DMSO, 500
MHz) δ 1.04 (6H, s, 2 x CH3), 1.05 (6H, s, 2 x CH3), 1.25 (2H, m, CH2), 1.41 (2H, m,
CH2(CH2NHCO)), 1.43 (4H, m, 2 x CH2), 1.57 (4H, m, 2 x CH2), 1.69 (3H, s, C=CCH3),
1.71 (3H, s, C=CCH3), 1.85 (2H, quin, J=6.3, CH2(CH2NH2)), 1.98 (1H, m,
CH2(CH2COOH)), 2.00 (3H, s, C=CCH3), 2.01 (1H, m, CH2(CH2COOH)), 2.02 (4H, m,
2 x C=CCH2), 2.07 (3H, s, C=CCH3), 2.10 (2H, d, J=50, CH2(COOH)), 2.14 (3H, s,
C=CCH3), 3.02 (2H, t, J=7.5, CH2NHCO), 4.21 (1H, bs, CH(COOH)), 4.37 (2H, m,
CH2N), 4.48 (2H, d, J=3.4, CH2(NHAr)), 6.20 (1H, d, J=17.0, C=CH), 6.28 (2H, m,
C=CH), 6.44 (2H, m, C=CH), 6.65 (1H, d, J=15.0, C=CH), 6.62 (2H, d, J=10, ArH), 6.65

90

(1H, d, J=15.0, C=CH), 6.72 (1H, s, C=CH), 6.77 (1H, d, J=15.0, C=CH), 6.90 (1H, m,
NH(Ar)), 7.05 (1H, dd, J=15.1, 11.7, C=CH), 7.09 (1H, bs, HO(Ar)), 7.63 (2H, d,
J=10.0, ArH), 7.82 (1H, s, ArH), 8.00 (1H, s, NH(COAr)), 8.05 (1H, m, ArH), 8.05 (2H,
m, C=CH), 8.61 (1H, s, ArH), 8.72 (1H, d, J=6.84, ArH), 11.90 (1H, bs, HO(CO));
HRMS (ESI+) m/z 1056.6438 (M+, C45H65N2 requires 1056.6439).
Separation of α and γ FA-A2C products by chromatotron was achieved with
(25% MeOH in CH2Cl2) giving two red products in low yields: α-UV-Vis (DMSO) λmax
293.5 nm, 336.3 nm, 441.6 nm; γ-UV-Vis (DMSO) λmax 294.6 nm, 336.3 nm, 439.2 nm.
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